EA200701084A1 - Поливалентные вакцины, содержащие рекомбинантные вирусные векторы - Google Patents

Поливалентные вакцины, содержащие рекомбинантные вирусные векторы

Info

Publication number
EA200701084A1
EA200701084A1 EA200701084A EA200701084A EA200701084A1 EA 200701084 A1 EA200701084 A1 EA 200701084A1 EA 200701084 A EA200701084 A EA 200701084A EA 200701084 A EA200701084 A EA 200701084A EA 200701084 A1 EA200701084 A1 EA 200701084A1
Authority
EA
Eurasian Patent Office
Prior art keywords
antigens
cleavage
relates
present
vaccines containing
Prior art date
Application number
EA200701084A
Other languages
English (en)
Other versions
EA012037B1 (ru
Inventor
Мензо Янс Эмко Хавенга
Роналд Вогелс
Джералд Сэдофф
Дэвид Хоун
Ясир Абдул Вахид Скейки
Катарина Радошевич
Original Assignee
Круселл Холланд Б.В.
ЭЙРАС ГЛОУБАЛ ТиБи ВЭКСИН ФАУНДЕЙШН
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Круселл Холланд Б.В., ЭЙРАС ГЛОУБАЛ ТиБи ВЭКСИН ФАУНДЕЙШН filed Critical Круселл Холланд Б.В.
Publication of EA200701084A1 publication Critical patent/EA200701084A1/ru
Publication of EA012037B1 publication Critical patent/EA012037B1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/04—Mycobacterium, e.g. Mycobacterium tuberculosis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • A61K35/761—Adenovirus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/06—Antibacterial agents for tuberculosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/35—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Mycobacteriaceae (F)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/523—Bacterial cells; Fungal cells; Protozoal cells expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5256—Virus expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55544—Bacterial toxins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10341—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Abstract

Настоящее изобретение относится к вакцинам, содержащим рекомбинантные векторы, такие как рекомбинантные аденовирусы. Векторы содержат гетерологичные последовательности нуклеиновых кислот, кодирующие по меньшей мере два антигена из одной или более вызывающих туберкулез бациллы. Настоящее изобретение относится также к применению специфических сайтов узнавания протеаз, связывающих антигены, посредством которых кодируемые антигены разделяются после расщепления. После расщепления антигены способствуют иммунному ответу раздельным образом. Рекомбинантные векторы могут содержать нуклеиновую кислоту, кодирующую расщепление линкеров и разделение антигенов под действием протеаз. Кроме того, настоящее изобретение относится к применению генетических адъювантов, кодируемых рекомбинантными векторами, при котором такие генетические адъюванты могут быть также расщеплены при наличии расщепляющих линкеров и специфической протеазы.
EA200701084A 2004-11-16 2005-11-15 Поливалентные вакцины, содержащие рекомбинантные вирусные векторы EA012037B1 (ru)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US62825304P 2004-11-16 2004-11-16
EP04106074 2004-11-25
US65111305P 2005-02-08 2005-02-08
PCT/EP2005/055984 WO2006053871A2 (en) 2004-11-16 2005-11-15 Multivalent vaccines comprising recombinant viral vectors

Publications (2)

Publication Number Publication Date
EA200701084A1 true EA200701084A1 (ru) 2007-10-26
EA012037B1 EA012037B1 (ru) 2009-06-30

Family

ID=34929936

Family Applications (1)

Application Number Title Priority Date Filing Date
EA200701084A EA012037B1 (ru) 2004-11-16 2005-11-15 Поливалентные вакцины, содержащие рекомбинантные вирусные векторы

Country Status (14)

Country Link
US (3) US8012467B2 (ru)
EP (1) EP1812580B1 (ru)
JP (1) JP4838259B2 (ru)
KR (1) KR101255870B1 (ru)
CN (2) CN102220357B (ru)
AU (2) AU2005305869B2 (ru)
BR (1) BRPI0518933A2 (ru)
CA (1) CA2586620C (ru)
EA (1) EA012037B1 (ru)
MX (1) MX2007005256A (ru)
NZ (2) NZ581306A (ru)
SG (2) SG159554A1 (ru)
WO (1) WO2006053871A2 (ru)
ZA (1) ZA200703838B (ru)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050232900A1 (en) * 1999-05-18 2005-10-20 Crucell Holland B.V. Serotype of adenovirus and uses thereof
US6492169B1 (en) 1999-05-18 2002-12-10 Crucell Holland, B.V. Complementing cell lines
NZ581306A (en) 2004-11-16 2011-03-31 Crucell Holland Bv Multivalent vaccines comprising recombinant viral vectors
US20090110695A1 (en) * 2006-03-27 2009-04-30 Menzo Jans Emko Havenga Compositions Comprising a Recombinant Adenovirus and an Adjuvant
PL2118128T3 (pl) * 2007-01-15 2013-03-29 Glaxosmithkline Biologicals Sa Białka fuzyjne zawierające antygeny odrzucenia nowotworu NY-ESO-1 i LAGE-1
GB0719509D0 (en) * 2007-10-05 2007-11-14 Isis Innovation Molecular adjuvant
DK2238255T3 (da) 2007-12-27 2013-11-18 Univ Zuerich Replikationsdefekte arenavirusvektorer
US20100015171A1 (en) 2008-07-15 2010-01-21 Statens Serum Institute Vaccines comprising tb 10.4
ES2890230T3 (es) * 2008-07-16 2022-01-18 Baylor Res Institute Vacuna contra el VIH basada en el direccionamiento de Gag y Nef maximizado a células dendríticas
JP5770633B2 (ja) 2008-11-03 2015-08-26 クルセル ホランド ベー ヴェー アデノウイルスベクターの産生方法
HUE042397T2 (hu) 2008-11-18 2019-06-28 Beth Israel Deaconess Medical Ct Inc Javított sejtes immunogenitású vírusellenes oltóanyagok
MX370744B (es) * 2009-04-24 2019-12-20 Una vacuna antituberculosis tb para evitar la reactivación.
EA023816B1 (ru) 2010-02-15 2016-07-29 Круселл Холланд Б.В. СПОСОБ ПРОДУЦИРОВАНИЯ ВИРУСНЫХ ЧАСТИЦ Ad26
GB201008512D0 (en) 2010-05-21 2010-07-07 Health Prot Agency Mycobacterial antigen composition
AP3390A (en) * 2010-09-20 2015-08-31 Crucell Holland Bv Therapeutic vaccination against active tuberculosis
CN102154324B (zh) * 2010-12-29 2012-11-28 兰州大学 结核分枝杆菌融合蛋白Mtb10.4-Hsp16.3的构建、表达和纯化方法及其应用
CN102260712B (zh) * 2011-05-31 2013-10-02 北京锤特生物科技有限公司 溶肿瘤能力增强的B型人腺病毒Ad11突变体的构建和应用
KR101983989B1 (ko) 2011-11-28 2019-05-31 얀센 백신스 앤드 프리벤션 비.브이. 인플루엔자 바이러스 백신 및 이의 용도
WO2013135615A1 (en) 2012-03-12 2013-09-19 Crucell Holland B.V. Batches of recombinant adenovirus with altered terminal ends
US8932607B2 (en) 2012-03-12 2015-01-13 Crucell Holland B.V. Batches of recombinant adenovirus with altered terminal ends
WO2013158061A1 (en) * 2012-04-16 2013-10-24 Aeras Global Tb Vaccine Foundation Recombinant mycobacterium encoding a heparin-binding hemagglutinin (hbha) fusion protein and uses thereof
US10357555B2 (en) 2012-07-10 2019-07-23 Transgene Sa Mycobacterial antigen vaccine
US9809801B2 (en) 2013-03-15 2017-11-07 Université De Genève Anti-mycobacterial vaccines
CN103304670B (zh) * 2013-06-03 2015-09-16 中国人民解放军第三〇九医院 结核分枝杆菌特异性融合蛋白疫苗ab及其制备和应用
NZ717156A (en) 2013-09-19 2022-04-29 Janssen Vaccines & Prevention Bv Improved adenovirus formulations
CN103865934B (zh) * 2014-03-26 2017-02-22 中国人民解放军成都军区疾病预防控制中心 银环毒素抗原表位基因及其在基因疫苗及抗原制备中的应用
ZA201608812B (en) 2014-06-26 2019-08-28 Janssen Vaccines & Prevention Bv Antibodies and antigen-binding fragments that specifically bind to microtubule-associated protein tau
BR112016030183A2 (pt) 2014-06-26 2017-11-14 Janssen Vaccines & Prevention Bv anticorpos e fragmentos de ligação ao antígeno que se ligam especificamente à proteína tau associada a microtúbulos
AU2016249798B2 (en) 2015-04-14 2022-05-26 Janssen Vaccines And Prevention B.V. Recombinant adenovirus expressing two transgenes with a bidirectional promoter
AU2016275619B2 (en) * 2015-06-12 2019-09-19 Glaxosmithkline Biologicals Sa Adenovirus polynucleotides and polypeptides
CA3001050C (en) 2015-10-06 2023-03-28 Janssen Vaccines & Prevention B.V. Method for preventing surface-induced degradation of viruses using cyclodextrins
EP3455358B1 (en) 2016-05-12 2020-08-26 Janssen Vaccines & Prevention B.V. Potent and balanced bidirectional promoter
ES2821876T3 (es) 2016-06-20 2021-04-28 Janssen Vaccines & Prevention Bv Promotor bidireccional potente y equilibrado
US11230572B2 (en) 2016-10-17 2022-01-25 Beth Israel Deaconess Medical Center, Inc. Signature-based human immunodeficiency virus (HIV) envelope (Env) trimer vaccines and methods of using the same
CN106754758A (zh) * 2016-12-29 2017-05-31 汕头大学医学院 一种含细胞因子佐剂的重组肠道病毒表型混合系统的构建方法及其应用
KR102111244B1 (ko) 2017-02-09 2020-05-15 얀센 백신스 앤드 프리벤션 비.브이. 이종 유전자의 발현을 위한 강력한 짧은 프로모터
CN107365365B (zh) * 2017-08-30 2021-01-01 广州医科大学附属第一医院 重组表达的腺病毒纤毛蛋白肽、腺病毒亚单位疫苗及其制备方法
CN107602672B (zh) * 2017-08-30 2021-06-18 广州医科大学附属第一医院 重组表达的腺病毒纤毛蛋白肽、腺病毒亚单位疫苗及其制备方法
WO2019081750A1 (en) * 2017-10-27 2019-05-02 Statens Serum Institut VACCINE AGAINST POLYGENIC INFLUENZA
EP4338727A1 (en) 2022-09-14 2024-03-20 Roquette Freres Adenovirus formulations

Family Cites Families (64)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2144394T3 (es) 1989-09-19 2000-06-16 Innogenetics Nv Polipeptidos y peptidos recombinantes, acidos nucleicos que los codifican y utilizacion de dichos polipeptidos y peptidos para el diagnostico de la tuberculosis.
EP0499003A1 (en) 1991-02-14 1992-08-19 N.V. Innogenetics S.A. Polypeptides and peptides, particularly recombinant polypeptides and peptides, nucleic acids coding for the same and use of these polypeptides and peptides in the diagnosis of tuberculosis
US6641814B1 (en) 1997-04-02 2003-11-04 Statens Serum Institut Nucleic acids fragments and polypeptide fragments derived from M. tuberculosis
DK79893D0 (da) 1993-07-02 1993-07-02 Statens Seruminstitut New vaccine
US5955077A (en) 1993-07-02 1999-09-21 Statens Seruminstitut Tuberculosis vaccine
US6599510B1 (en) 1993-11-23 2003-07-29 The Regents Of The University Of California Abundant extracellular products and methods for their production and use
ATE407945T1 (de) 1993-11-23 2008-09-15 Univ California Reichlich vorhandene extrazelluläre produkte und methoden zu ihrer herstellung sowie ihre verwendung
US5736524A (en) * 1994-11-14 1998-04-07 Merck & Co.,. Inc. Polynucleotide tuberculosis vaccine
WO1996037219A1 (en) 1995-05-23 1996-11-28 The Regents Of The University Of California Abundant extracellular products and methods for their production and use
US6592877B1 (en) 1995-09-01 2003-07-15 Corixa Corporation Compounds and methods for immunotherapy and diagnosis of tuberculosis
US6290969B1 (en) 1995-09-01 2001-09-18 Corixa Corporation Compounds and methods for immunotherapy and diagnosis of tuberculosis
ES2262595T3 (es) 1995-09-01 2006-12-01 Corixa Corporation Compuestos y metodos para la inmunoterapia y diagnostico de la tuberculosis.
US6338852B1 (en) 1995-09-01 2002-01-15 Corixa Corporation Compounds and methods for diagnosis of tuberculosis
US6458366B1 (en) 1995-09-01 2002-10-01 Corixa Corporation Compounds and methods for diagnosis of tuberculosis
ES2378051T3 (es) 1995-09-01 2012-04-04 Corixa Corporation Compuestos y métodos para el diagnóstico de la tubercolosis.
US6087163A (en) 1997-02-06 2000-07-11 The Public Health Research Institute Of The City Of New York, Inc. Mycobacterium tuberculosis specific proteins and genes, mixtures of anitgens and uses thereof
WO1998010087A1 (en) 1996-09-06 1998-03-12 Trustees Of The University Of Pennsylvania Chimpanzee adenovirus vectors
TR199901569T2 (xx) 1996-10-11 2000-12-21 Corixa Corporation T�berk�lozun te�hisi i�in bile�ikler ve y�ntemler.
JP2001512435A (ja) 1997-01-21 2001-08-21 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア 豊富な細胞外産物ならびにそれらの産生および使用方法
US6544522B1 (en) 1998-12-30 2003-04-08 Corixa Corporation Fusion proteins of mycobacterium tuberculosis antigens and their uses
US6627198B2 (en) 1997-03-13 2003-09-30 Corixa Corporation Fusion proteins of Mycobacterium tuberculosis antigens and their uses
US6350456B1 (en) 1997-03-13 2002-02-26 Corixa Corporation Compositions and methods for the prevention and treatment of M. tuberculosis infection
AU740545B2 (en) 1997-04-02 2001-11-08 Statens Serum Institut Nucleic acid fragments and polypeptide fragments derived from M. tuberculosis
US7037510B2 (en) * 1997-04-18 2006-05-02 Statens Serum Institut Hybrids of M. tuberculosis antigens
US6613881B1 (en) 1997-05-20 2003-09-02 Corixa Corporation Compounds for immunotherapy and diagnosis of tuberculosis and methods of their use
US6555653B2 (en) 1997-05-20 2003-04-29 Corixa Corporation Compounds for diagnosis of tuberculosis and methods for their use
US6436409B1 (en) 1997-07-16 2002-08-20 Institut Pasteur Polynucleotide functionally coding for the LHP protein from Mycobacterium tuberculosis, its biologically active derivative fragments, as well as methods using the same
NZ504951A (en) 1997-11-10 2001-06-29 Statens Seruminstitut Nucleic acid fragments and polypeptide fragments derived from M. tuberculosis
TWI243169B (en) 1998-03-02 2005-11-11 Nissan Chemical Ind Ltd Optically active epoxy compound
CA2326598C (en) 1998-04-07 2014-06-10 Corixa Corporation Fusion proteins of mycobacterium tuberculosis antigens and their uses
US20020150592A1 (en) 1998-09-18 2002-10-17 The Regents Of The University Of California Abundant extracellular products and methods for their production and use
WO2000021983A2 (en) 1998-10-08 2000-04-20 Statens Serum Institut Tuberculosis vaccine and diagnostic reagents based on antigens from the mycobacterium tuberculosis cell
AU2594500A (en) 1998-12-24 2000-07-31 Corixa Corporation Methods for using mycobacterium tuberculosis molecules as immunological adjuvants
US6465633B1 (en) 1998-12-24 2002-10-15 Corixa Corporation Compositions and methods of their use in the treatment, prevention and diagnosis of tuberculosis
US20030027774A1 (en) 1999-03-18 2003-02-06 Ronald C. Hendrickson Tuberculosis antigens and methods of use therefor
ES2354578T3 (es) 1999-05-17 2011-03-16 Crucell Holland B.V. Adenovirus recombinante humano de serotipo ad26.
US6492169B1 (en) 1999-05-18 2002-12-10 Crucell Holland, B.V. Complementing cell lines
US7468181B2 (en) 2002-04-25 2008-12-23 Crucell Holland B.V. Means and methods for the production of adenovirus vectors
JP5010079B2 (ja) 1999-07-13 2012-08-29 スタテンズ セーラム インスティテュート マイコバクテリウム・ツベルクローシスｅｓａｔ−６遺伝子ファミリーベースの結核ワクチン及び診断法
US20020039583A1 (en) 1999-09-30 2002-04-04 Subjeck John R. Stress protein compositions and methods for prevention and treatment of cancer and infectious disease
US6984384B1 (en) 1999-09-30 2006-01-10 Health Research, Inc. Stress protein compositions and methods for prevention and treatment of cancer and infectious disease
EP1229931A4 (en) 1999-10-07 2003-05-28 Corixa Corp FUSION PROTEINS FROM MYCOBACTERIUM TUBERCULOSIS
EP1517913B9 (en) 1999-10-07 2007-08-29 Corixa Corporation A mycobacterium tuberculosis coding sequence for exression of heterologous proteins
AU2001241738A1 (en) 2000-02-25 2001-09-03 Corixa Corporation Compounds and methods for diagnosis and immunotherapy of tuberculosis
GB0006693D0 (en) 2000-03-20 2000-05-10 Glaxo Group Ltd Vaccine
WO2001079274A2 (en) 2000-04-19 2001-10-25 Statens Serum Institut Tuberculosis antigens and methods of use thereof
US7754201B2 (en) 2000-06-02 2010-07-13 GenPhar, Inc Method of vaccination through serotype rotation
US20020155127A1 (en) * 2000-06-02 2002-10-24 Danher Wang Genetic vaccine against human immunodeficiency virus
CA2413959C (en) 2000-06-20 2015-07-07 Corixa Corporation Fusion proteins of mycobacterium tuberculosis
WO2002092132A2 (en) * 2001-01-05 2002-11-21 Corixa Corporation Microparticles and methods for delivery of recombinant viral vaccines
WO2003000851A2 (en) 2001-06-22 2003-01-03 The Trustees Of The University Of Pennsylvania Method for rapid screening of bacterial transformants and novel simian adenovirus proteins
HU230364B1 (hu) 2001-11-21 2016-03-29 The Trustees Of The University Of Pennsylvania Simian adenovírus nukleinsav és aminosav-szekvencia, azt tartalmazó vektorok, és eljárások annak alkalmazására
AU2003213118A1 (en) * 2002-02-15 2003-09-09 Corixa Corporation Fusion proteins of mycobacterium tuberculosis
JP4495588B2 (ja) 2002-04-25 2010-07-07 クルセル ホランド ベー ヴェー 安定なアデノウイルスベクターおよびその増殖方法
WO2004006952A2 (en) 2002-07-13 2004-01-22 Statens Serum Institut Therapeutic tuberculosis vaccines
AU2003288273A1 (en) * 2002-10-23 2004-05-13 Crucell Holland B.V. New settings for recombinant adenoviral-based vaccines
EP1606397A1 (en) 2003-03-17 2005-12-21 Merck & Co., Inc. Adenovirus serotype 24 vectors, nucleic acids and virus produced thereby
US7709224B2 (en) 2003-06-03 2010-05-04 Biosante Pharmaceuticals, Inc. Compositions and methods for enhanced expression of recombinant polypeptides from a single vector using a peptide cleavage site
KR100992646B1 (ko) * 2003-07-09 2010-11-05 제이에스알 가부시끼가이샤 파장판
EP1663114A2 (en) * 2003-09-18 2006-06-07 Merck & Co., Inc. Therapeutic immunization of hiv-infected individuals
WO2005061534A2 (en) * 2003-12-23 2005-07-07 Statens Serum Institut Improved tuberculosis vaccines
NZ581306A (en) * 2004-11-16 2011-03-31 Crucell Holland Bv Multivalent vaccines comprising recombinant viral vectors
KR101329323B1 (ko) * 2004-12-01 2013-11-14 아에라스 글로벌 티비 백신 파운데이션 엔도솜을 이탈하는 능력이 보강된 재조합 비씨지 균주
BRPI0613784A2 (pt) 2005-07-21 2011-02-01 Abbott Lab expressão de gene múltipla incluindo constructos sorf e métodos com poliproteìnas, pro-proteìnas e proteólise

Also Published As

Publication number Publication date
CN101090974A (zh) 2007-12-19
CN102220357B (zh) 2013-12-25
US8012467B2 (en) 2011-09-06
EP1812580A2 (en) 2007-08-01
AU2011200749B2 (en) 2012-03-01
ZA200703838B (en) 2012-07-25
WO2006053871A3 (en) 2006-12-21
NZ581306A (en) 2011-03-31
EP1812580B1 (en) 2014-12-17
US8202723B2 (en) 2012-06-19
KR101255870B1 (ko) 2013-04-17
CN102220357A (zh) 2011-10-19
CA2586620C (en) 2014-06-03
SG159555A1 (en) 2010-03-30
US8609402B2 (en) 2013-12-17
AU2011200749B9 (en) 2012-04-05
BRPI0518933A2 (pt) 2008-12-16
AU2011200749A1 (en) 2011-03-10
NZ555907A (en) 2009-12-24
EA012037B1 (ru) 2009-06-30
JP4838259B2 (ja) 2011-12-14
MX2007005256A (es) 2008-03-11
US20090123438A1 (en) 2009-05-14
CA2586620A1 (en) 2006-05-26
AU2005305869A1 (en) 2006-05-26
KR20070091620A (ko) 2007-09-11
JP2008520198A (ja) 2008-06-19
US20110281347A1 (en) 2011-11-17
US20110256166A1 (en) 2011-10-20
AU2005305869B2 (en) 2010-12-09
SG159554A1 (en) 2010-03-30
CN101090974B (zh) 2011-05-11
WO2006053871A2 (en) 2006-05-26

Similar Documents

Publication Publication Date Title
EA200701084A1 (ru) Поливалентные вакцины, содержащие рекомбинантные вирусные векторы
NO20072470L (no) Malariaigangsetter/forsterkervaksine
RU2020132040A (ru) Общие неоантигены
WO2007106476A3 (en) Compositions and methods for enhancing the immunogenicity of antigens
EA200901060A1 (ru) Новый способ и композиции
TW200621287A (en) Vaccines
WO2007062656A3 (en) A nucleotide vaccine
WO2018193063A3 (en) NEW VACCINES AGAINST MALARIA AND ANTIBODIES BINDING PLASMODIUM SPOROZOIDS
WO2005012537A3 (en) Adenoviral vector-based vaccines
EA201170812A1 (ru) Способы и композиции для применения вакцины против кокцидиоза
IN2009CN03372A (ru)
MX2019003156A (es) Combinaciones de vacunas novedosas contra el virus del zika y construcciones de anticuerpos de adn para usar contra el virus del zika.
MX2022014943A (es) Polipéptidos de coronavirus 2 causante del síndrome respiratorio agudo severo (sars-cov-2) y usos de los mismos para propositos de vacuna.
WO2012114125A3 (en) Treatment and prevention of malaria
WO2018172259A3 (en) IMPROVED LI VACCINE ADJUVANT
WO2001074845A3 (en) Immunogenic peptides derived from prostate-specific membrane antigen (psma) and uses thereof
ATE435660T1 (de) Immunogenes polypeptid bestehend aus optimierten kryptischen peptiden aus tumorantigenen und seine verwendungen
Bezerra et al. Constitutive expression and characterization of a surface SRS (NcSRS67) protein of Neospora caninum with no orthologue in Toxoplasma gondii
EA201171430A1 (ru) Пептиды
MX2010010025A (es) Proteina de fusion con direccionamiento de antigenos vacunales a celulas presentadoras de antigeno y sus aplicaciones.
MX2022002628A (es) Proteinas de fusion y usos de las mismas.
WO2002051237A3 (en) Helicobacter proteins, nucleic acids and uses thereof
JP2017500030A5 (ru)
ATE420181T1 (de) Neues oberflächenexponiertes, immunglobulin d bindendes protein aus moraxella catarrhalis
WO2004056316A8 (en) Vaccines against hiv-1 tat protein to generate neutralizing antibodies